Learn About Respiratory Syncytial Virus (RSV) Infection

What is the definition of Respiratory Syncytial Virus (RSV) Infection?
Respiratory syncytial virus (RSV) is a common virus that causes infections of the respiratory tract and lungs. Respiratory syncytial virus mostly affects children but can also infect adults.
Save information for later
Sign Up
What are the symptoms of Respiratory Syncytial Virus (RSV) Infection?
Symptoms of respiratory syncytial virus can be similar to a mild cold in older, healthy children and adults. In babies under 12 months, premature infants, individuals with heart or lung disease, immunocompromised individuals, older adults, and individuals with other serious medical problems, respiratory syncytial virus can cause severe infection. Symptoms of respiratory syncytial virus infection usually appear within 4-to-6 days after infection. Symptoms of respiratory syncytial virus infection include decreased appetite, runny nose, congestion, cough, sneezing, fever, sore throat, headache, and wheezing. Symptoms of severe respiratory syncytial virus infection may also include fever; severe cough; wheezing; short, shallow, and rapid breathing or difficulty breathing; bluish skin; poor appetite; extreme fatigue; and irritability.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Respiratory Syncytial Virus (RSV) Infection?
Treatment for respiratory syncytial virus infection is focused on supportive and self-care, including over-the-counter pain medications, such as acetaminophen; saline nasal drops; cough medicine; and fluids. (Note that children should never be given aspirin. In addition, children under four years of age should not be given cough medicine unless prescribed by a physician.) Antibiotics may be prescribed if bacterial pneumonia develops. Patients with severe respiratory syncytial virus infection are treated in the hospital. In-hospital treatment for patients with severe respiratory syncytial virus infection may include intravenous fluids, antibiotics, humidified oxygen, intubation, and mechanical ventilation.
Who are the top Respiratory Syncytial Virus (RSV) Infection Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Respiratory Syncytial Virus (RSV) Infection Clinical Trials?
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV ΔNS2 Δ1313 I1314L, Lot RSV#006A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age, RSV-Seronegative Infants and Children 6 to 24 Months of Age, and Infants 4 to 6 Months of Age

Summary: Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children around the world. This study will evaluate the safety and immune response to a RSV vaccine in three groups of participants: healthy children who have already had an RSV infection (RSV seropositive), healthy infants and children who have not already had an RSV infection (RSV seronegative), and h...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Sample Collection to Facilitate the Performance Evaluation of the LumiraDx Point of Care Device for the Detection of Influenza A/B, Respiratory Syncytial Virus (RSV) & COVID-19 (SARS-COV-2 Virus)

Summary: Collection of Nasal Swabs, Throat Swabs and Saliva Samples from patients presenting at their designated care or testing facility displaying symptoms of either Influenza, Respiratory Syncytial Virus (RSV), SARS-CoV-2 or those who have been in recent contact with SARS-CoV-2 positive patients. Collected samples will aid the development, calibration and performance evaluation of the LumiraDx POC Test.

What are the Latest Advances for Respiratory Syncytial Virus (RSV) Infection?
Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals.
Probiotics as a biotherapeutics for the management and prevention of respiratory tract diseases.
Tired of the same old research?
Check Latest Advances
Molnupiravir and Its Antiviral Activity Against COVID-19.